Posters

Effects of intravitreal ranibizumab and aflibercept injections on the corneal endothelium in the treatment of exudative age-related macular degeneration

Poster Details

First Author: T.Celik TURKEY

Co Author(s):                        

Abstract Details

Purpose:

To evaluate the effects intravitreal ranibizumab and aflibercept injections on the corneal endothelium in the treatment of exudative age-related macular degeneration (ARMD).

Setting:

Department of Ophthalmology, Bulent Ecevit University Faculty of Medicine, Zonguldak, Turkey

Methods:

Forty-two eyes of 42 exudative ARMD patients were included in this prospective clinical study. Group 1( n=21) received 0.5 mg/0.05 ml ranibizumab and group 2 received 2.0 mg/0.05 ml aflibercept monthly until 3 months and then as needed. Specular microscopy was performed to evaluate the countand morphology of corneal endothelium cells. The outcomes prior to injection and after the 3 consecutive monthly injections were compared.

Results:

The mean age of the groups were 64.84± 7.24 and 66.40± 6.12, respectively. There were 10 male (48%) and 11 female (52%) in group 1 and 9 (43%) male 12 (57%) female in group 2. No significant difference was found in age and gender distribution. (p=0.14, p=0.32, respectively) There was no significant difference between the groups in endothelial cell count (Group 1, p = 0.72; group 2, p = 0.66), pleomorphism (Group 1, p = 0.48; group 2, p = 0.54) and polymegathism (group1, p = 0.26; group 2, p = 0.32) before injection and after tthird injections.

Conclusions:

There was not any destructive effect of the ranibizumab and aflibercept treatment on the corneal epithelium after 3 injections.Both intravitreal ranibizumab and aflibercept injections monthly for three months were found safe in the treatment of ARMD.

Financial Disclosure:

NONE